Market Herald logo

Subscribe

Be the first with the news that moves the market
  • BioSyent (RX) subsidiary BioSyent launches of new FeraMAX® Pd Powder 15
  • In November 2020, BioSyent Pharma Inc. launched FeraMAX® Pd Therapeutic 150
  • Together, these transitions to the patented PDIC formulation mark a milestone in the innovation history of FeraMAX®
  • FeraMAX® Pd Powder 15 is presented in new packaging, appealing to children with its new mascot, ‘Max the monkey’
  • BioSyent is committed to delivering innovation in iron therapy with its current and future pipeline
  • BioSyent Inc. (RX) is down 0.43 per cent, trading at C$6.90 at 2:01 pm ET

BioSyent Inc. (RX) subsidiary BioSyent Pharma lanches FeraMAX® Pd Powder 15 in Canada.

FeraMAX® Pd Powder 15 is the second product incorporating Polydextrose-Iron Complex (PDIC), a patented oral iron supplement delivery system.

In November 2020, BioSyent Pharma Inc. launched FeraMAX® Pd Therapeutic 150, the first product using the PDIC formulation in Canada.

Together, these transitions to the patented PDIC formulation mark a milestone in the innovation history of FeraMAX® and strengthen BioSyent’s commitment to the management of iron deficiency and iron-deficiency anemia in Canada.

FeraMAX® Pd Powder 15 is presented in new packaging, appealing to children with its new mascot, ‘Max the monkey’. The packaging enables convenient product selection by the pharmacist and ease of identification by the parent.

FeraMAX® Pd Powder 15 helps to make iron therapy convenient for children with its differentiating benefits. It does not stain teeth and has a pleasant grape/raspberry flavour to support adherence to treatment. FeraMAX® Pd Powder 15 is well-tolerated, vegan certified by VegeCert, and is gluten, lactose, and alcohol-free.

FeraMAX® Pd Powder 15 will replace FeraMAX® Powder at Canadian pharmacies and shipments in an 83g bottle configuration have commenced.

FeraMAX® Pd is made with a homogeneous polysaccharide, Polydextrose, linked to ferric (Fe3+) elemental iron to form the proprietary Polydextrose Iron Complex. This unique and patented formulation is the foundation of future product innovations in oral iron supplementation for BioSyent.

This formulation differs from the previous FeraMAX® formulation which used a heterogeneous mixture of polysaccharides to form the Polysaccharide Iron Complex (“PIC”). The PDIC delivery system provides a more uniform molecular structure for the iron complex.

The Introduction of FeraMAX® Pd Powder 15 in the PDIC formulation with the same trusted quality, advances the legacy of FeraMAX®, which has made it the number one recommended iron supplement brand by Canadian physicians and pharmacists for six consecutive years, including 2021.

BioSyent is committed to delivering innovation in iron therapy with its current and future pipeline and thanks healthcare providers and patients who have trusted FeraMAX® for their iron health for more than a decade.

BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty, and international business units.

BioSyent Inc. (RX) is down 0.43 per cent, trading at C$6.90 at 2:01 pm ET.

More From The Market Herald
Rakovina Therapeutics Inc. (TSXV:RKV) - Executive Chairman- Jeffrey Bacha.

" Rakovina (TSXV:RKV) advancing trial programs for cancer treatment

Rakovina Therapeutics (RKV) is advancing its programs for malignant tumour treatment therapies.
MedMira Inc. - CEO, Hermes Chan

" MedMira (TSXV:MIR) gets CE mark during new device regulations

MedMira Inc. (MIR) has received the CE mark for three of seven products submitted this year.
The Market Herald Video

" Empower Clinics (CSE:CBDT) accredited for Covid-19 mobile testing in B.C.

Empower Clinics (CBDT) has received accreditation for its COVID-19 mobile testing solutions.

" Revive (CSE:RVV) gets FDA OK for Bucillamine trials to treat COVID-19

Revive Therapeutics (RVV), a cannabis and psychedelic healthcare company has received feedback from the U.S. FDA to help advance Bucillamine.